Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
64.7 USD | -0.33% | -0.89% | -20.07% |
05-07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
05-02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.07% | 80.95B | |
+32.75% | 698B | |
+26.51% | 568B | |
-4.58% | 358B | |
+19.57% | 328B | |
+3.44% | 283B | |
+16.34% | 238B | |
+6.68% | 203B | |
-9.08% | 198B | |
+8.96% | 165B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90